We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cannabis Stock Tilray Brands Skyrockets 94.5%: Time to Buy, Sell or Hold?
Read MoreHide Full Article
Key Takeaways
Tilray Brands shares soared 94.5% in three months, driven by strong Q1 results and investor optimism.
TLRY's medical division expanded in Panama, Europe, and Australia through new launches and partnerships.
TLRY Q1 net income improved to $1.5M from a $34.7M loss, reflecting cost control and operational efficiency.
In the past three months, shares of Tilray Brands (TLRY - Free Report) have skyrocketed 94.5%, significantly outperforming the industry’s 2.5% decline.
Image Source: Zacks Investment Research
TLRY stock has risen following a CNBC report citing optimism over potential federal rules for hemp-derived products and indications that President Donald Trump may relax marijuana restrictions. Shares have also risen on the back of the company achieving a record first-quarter net revenues of $210 million and a strengthened balance sheet.
The stock’s exceptional performance has left investors wondering whether to buy, hold or sell it. Let’s delve into the company’s fundamentals to gain a better understanding of how to play the stock amid this price rally.
Tilray Medical’s Expanding Global Footprint
Tilray Medical, a division of Tilray Brands, continues to expand its global medical cannabis footprint with key international developments. Through its joint venture with Top Tech Global Inc., the company established Solana Life Group in Panama, which has obtained regulatory approval to cultivate, manufacture, and distribute medical cannabis locally. Through this partnership, Tilray Medical aims to launch and expand the availability of medical cannabis products across Panama, improving access for patients in need.
TLRY also broadened its European presence by launching five new cannabis flower products in Germany, produced at its EU GMP-certified Neumünster facility. Also, the company’s wholly owned subsidiary, FL Group S.R.L, entered a strategic partnership with Italy’s Molteni to broaden the availability of Tilray Medical cannabis extracts for patients across Italy.
In Australia, Tilray Brand introduced its first medical cannabis edible, Good Supply Pastilles, a sugar-free, vegan-friendly option, underscoring its commitment to innovation and patient-focused treatment solutions worldwide.
Improved Net Income in Q1
Tilray Brands reported a strong improvement in profitability in the first quarter of fiscal 2026, achieving net income of $1.5 million compared to a net loss of $34.7 million in the year-ago period. The turnaround reflects the company’s continued focus on cost discipline, operational efficiency, and portfolio optimization. Adjusted net income also improved significantly to $3.9 million from an adjusted net loss of $6 million a year earlier, driven by lower SG&A expenses and reduced amortization.
Other Players in the Cannabis Space
Tilray Brands competes in an overcrowded market. It faces stiff competition from its peers, like Village Farms International (VFF - Free Report) and Curaleaf Holdings (CURLF - Free Report) , both of which are also pursuing international expansion and cost optimization strategies. As TLRY gains ground in international markets, competitive responses from Village Farms and Curaleaf could intensify.
Estimates for TLRY
The Zacks Consensus Estimate for fiscal 2026 sales implies a year-over-year improvement of 6.8%. Per the Zacks Consensus Estimate, loss per share for fiscal 2026 is expected to deteriorate 600% year over year. However, in the past 30 days, Tilray’ loss per share estimate for fiscal 2026 has moved north 6 cents.
Image Source: Zacks Investment Research
Key Challenges for TLRY
Tilray Brands is at an important point where changing global economic conditions could challenge how well its growing business can hold up. Despite continued momentum in revenues and profitability, the company struggles with persistent price compression and regulatory friction in Canada, including elevated excise taxes and constrained retail channels for cannabis beverages. These structural challenges could pressure margins in select business lines.
Across Europe, Tilray’s growth is facing some short-term challenges from permit delays in Portugal and quota restrictions in Germany, limiting cross-border cannabis distribution. Meanwhile, currency volatility, particularly the strengthening euro, might be an additional headwind to the company’s top-line performance.
Despite these headwinds, Tilray continued to execute its cost-optimization initiatives and strengthen its balance sheet, enabling the company to deliver a positive net income and maintain a stable outlook for fiscal 2026.
TLRY Stock Discounted Valuation
With a forward one-year price-to-sales (P/S) of 1.52X, Tilray’ shares are trading at a discount compared with the industry average of 3.16X. It has a Value Score of D at present.
Image Source: Zacks Investment Research
How to Play TLRY Stock?
While Tilray Brands continues to face regulatory and macroeconomic challenges across Canada and Europe, its strong fiscal first-quarter results, expanding global medical footprint and improved profitability highlight its steady progress. Investor optimism around potential U.S. policy shifts and sector tailwinds has further fueled the stock’s impressive rally. With this, Tilray Brands appears well-positioned to sustain its momentum and build on its recent gains.
Image: Bigstock
Cannabis Stock Tilray Brands Skyrockets 94.5%: Time to Buy, Sell or Hold?
Key Takeaways
In the past three months, shares of Tilray Brands (TLRY - Free Report) have skyrocketed 94.5%, significantly outperforming the industry’s 2.5% decline.
Image Source: Zacks Investment Research
TLRY stock has risen following a CNBC report citing optimism over potential federal rules for hemp-derived products and indications that President Donald Trump may relax marijuana restrictions. Shares have also risen on the back of the company achieving a record first-quarter net revenues of $210 million and a strengthened balance sheet.
The stock’s exceptional performance has left investors wondering whether to buy, hold or sell it. Let’s delve into the company’s fundamentals to gain a better understanding of how to play the stock amid this price rally.
Tilray Medical’s Expanding Global Footprint
Tilray Medical, a division of Tilray Brands, continues to expand its global medical cannabis footprint with key international developments. Through its joint venture with Top Tech Global Inc., the company established Solana Life Group in Panama, which has obtained regulatory approval to cultivate, manufacture, and distribute medical cannabis locally. Through this partnership, Tilray Medical aims to launch and expand the availability of medical cannabis products across Panama, improving access for patients in need.
TLRY also broadened its European presence by launching five new cannabis flower products in Germany, produced at its EU GMP-certified Neumünster facility. Also, the company’s wholly owned subsidiary, FL Group S.R.L, entered a strategic partnership with Italy’s Molteni to broaden the availability of Tilray Medical cannabis extracts for patients across Italy.
In Australia, Tilray Brand introduced its first medical cannabis edible, Good Supply Pastilles, a sugar-free, vegan-friendly option, underscoring its commitment to innovation and patient-focused treatment solutions worldwide.
Improved Net Income in Q1
Tilray Brands reported a strong improvement in profitability in the first quarter of fiscal 2026, achieving net income of $1.5 million compared to a net loss of $34.7 million in the year-ago period. The turnaround reflects the company’s continued focus on cost discipline, operational efficiency, and portfolio optimization. Adjusted net income also improved significantly to $3.9 million from an adjusted net loss of $6 million a year earlier, driven by lower SG&A expenses and reduced amortization.
Other Players in the Cannabis Space
Tilray Brands competes in an overcrowded market. It faces stiff competition from its peers, like Village Farms International (VFF - Free Report) and Curaleaf Holdings (CURLF - Free Report) , both of which are also pursuing international expansion and cost optimization strategies. As TLRY gains ground in international markets, competitive responses from Village Farms and Curaleaf could intensify.
Estimates for TLRY
The Zacks Consensus Estimate for fiscal 2026 sales implies a year-over-year improvement of 6.8%. Per the Zacks Consensus Estimate, loss per share for fiscal 2026 is expected to deteriorate 600% year over year. However, in the past 30 days, Tilray’ loss per share estimate for fiscal 2026 has moved north 6 cents.
Image Source: Zacks Investment Research
Key Challenges for TLRY
Tilray Brands is at an important point where changing global economic conditions could challenge how well its growing business can hold up. Despite continued momentum in revenues and profitability, the company struggles with persistent price compression and regulatory friction in Canada, including elevated excise taxes and constrained retail channels for cannabis beverages. These structural challenges could pressure margins in select business lines.
Across Europe, Tilray’s growth is facing some short-term challenges from permit delays in Portugal and quota restrictions in Germany, limiting cross-border cannabis distribution. Meanwhile, currency volatility, particularly the strengthening euro, might be an additional headwind to the company’s top-line performance.
Despite these headwinds, Tilray continued to execute its cost-optimization initiatives and strengthen its balance sheet, enabling the company to deliver a positive net income and maintain a stable outlook for fiscal 2026.
TLRY Stock Discounted Valuation
With a forward one-year price-to-sales (P/S) of 1.52X, Tilray’ shares are trading at a discount compared with the industry average of 3.16X. It has a Value Score of D at present.
Image Source: Zacks Investment Research
How to Play TLRY Stock?
While Tilray Brands continues to face regulatory and macroeconomic challenges across Canada and Europe, its strong fiscal first-quarter results, expanding global medical footprint and improved profitability highlight its steady progress. Investor optimism around potential U.S. policy shifts and sector tailwinds has further fueled the stock’s impressive rally. With this, Tilray Brands appears well-positioned to sustain its momentum and build on its recent gains.
With its cheap valuation and a Zacks Rank #2 (Buy), TLRY could serve as a selective play for investors seeking exposure to the industry’s gradual rebound. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.